JP2022505663A5 - - Google Patents

Info

Publication number
JP2022505663A5
JP2022505663A5 JP2021522078A JP2021522078A JP2022505663A5 JP 2022505663 A5 JP2022505663 A5 JP 2022505663A5 JP 2021522078 A JP2021522078 A JP 2021522078A JP 2021522078 A JP2021522078 A JP 2021522078A JP 2022505663 A5 JP2022505663 A5 JP 2022505663A5
Authority
JP
Japan
Prior art keywords
binding
fragment
domain
receptor
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021522078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505663A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/057702 external-priority patent/WO2020086745A1/en
Publication of JP2022505663A publication Critical patent/JP2022505663A/ja
Publication of JP2022505663A5 publication Critical patent/JP2022505663A5/ja
Pending legal-status Critical Current

Links

JP2021522078A 2018-10-23 2019-10-23 IgM-Fcベース及びIgA-Fcベースの多価結合分子 Pending JP2022505663A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862749429P 2018-10-23 2018-10-23
US62/749,429 2018-10-23
PCT/US2019/057702 WO2020086745A1 (en) 2018-10-23 2019-10-23 MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES

Publications (2)

Publication Number Publication Date
JP2022505663A JP2022505663A (ja) 2022-01-14
JP2022505663A5 true JP2022505663A5 (cg-RX-API-DMAC7.html) 2022-10-28

Family

ID=70331240

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021522078A Pending JP2022505663A (ja) 2018-10-23 2019-10-23 IgM-Fcベース及びIgA-Fcベースの多価結合分子

Country Status (11)

Country Link
US (1) US20210380701A1 (cg-RX-API-DMAC7.html)
EP (1) EP3870223A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022505663A (cg-RX-API-DMAC7.html)
KR (1) KR20210083260A (cg-RX-API-DMAC7.html)
CN (1) CN112839677A (cg-RX-API-DMAC7.html)
AU (1) AU2019368289A1 (cg-RX-API-DMAC7.html)
CA (1) CA3113268A1 (cg-RX-API-DMAC7.html)
IL (1) IL281901A (cg-RX-API-DMAC7.html)
MX (1) MX2021004660A (cg-RX-API-DMAC7.html)
SG (1) SG11202103720XA (cg-RX-API-DMAC7.html)
WO (1) WO2020086745A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015120474A1 (en) 2014-02-10 2015-08-13 Igm Biosciences, Inc. Iga multi-specific binding molecules
EP4011910A1 (en) 2014-04-03 2022-06-15 IGM Biosciences, Inc. Modified j-chain
PT3247728T (pt) 2015-01-20 2020-07-16 Igm Biosciences Inc Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas
KR102357312B1 (ko) 2015-03-04 2022-02-03 아이쥐엠 바이오사이언스 인코포레이티드 Cd20 결합 분자 및 그의 용도
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
AU2016249404B2 (en) 2015-04-17 2021-01-21 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
PT3355913T (pt) 2015-09-30 2024-12-18 Igm Biosciences Inc Moléculas de ligação com cadeia j modificada
ES2819870T3 (es) 2015-09-30 2021-04-19 Igm Biosciences Inc Moléculas de unión con cadena J modificada
WO2017196867A1 (en) 2016-05-09 2017-11-16 Igm Biosciences, Inc. Anti-pd-l1 antibodies
CA3055790A1 (en) 2017-04-07 2018-10-11 Igm Biosciences, Inc. Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
CN111787951B (zh) 2018-03-01 2025-06-17 Igm生物科学股份有限公司 影响IgM血清半衰期的IgM Fc和J链突变
JP2022544405A (ja) 2019-08-15 2022-10-18 アイジーエム バイオサイエンシズ インコーポレイテッド 免疫刺激性多量体型結合分子
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
US12285480B2 (en) 2020-03-11 2025-04-29 Nantcell, Inc. Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
JP2023522962A (ja) * 2020-04-22 2023-06-01 アイジーエム バイオサイエンシズ インコーポレイテッド Pd-1アゴニスト多量体結合分子
CN116813759B (zh) * 2022-03-21 2025-11-28 中国科学院微生物研究所 纳米抗体r14的构建体及其应用
CA3245061A1 (en) * 2022-04-07 2023-10-12 Repertoire Immune Medicines, Inc. T-CELL RECEIVER MULTIMERS AND THEIR USES
CN118369336A (zh) * 2022-04-15 2024-07-19 Im生技股份有限公司 具有改进半衰期的融合蛋白平台
US20240025996A1 (en) * 2022-07-11 2024-01-25 Fred Hutchinson Cancer Center Igm-multimerized single-domain antibodies that bind ror1
CN117466996A (zh) * 2022-07-29 2024-01-30 深圳市新产业生物医学工程股份有限公司 新型冠状病毒检测试剂盒及应用
WO2024073700A2 (en) * 2022-09-30 2024-04-04 Igm Biosciences, Inc. Methods of treating autoimmune disorders using multimeric anti-cd20/anti-cd3 antibodies
CN119505007A (zh) * 2023-08-23 2025-02-25 菲鹏生物股份有限公司 免疫球蛋白Fc区或恒定区

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997047732A2 (en) * 1996-06-14 1997-12-18 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
PL2604693T3 (pl) * 2008-07-21 2016-09-30 Jednołańcuchowe cząsteczki TNFSF
EP2760891B1 (en) * 2011-09-26 2018-11-07 JN Biosciences LLC Hybrid constant regions
WO2015120474A1 (en) * 2014-02-10 2015-08-13 Igm Biosciences, Inc. Iga multi-specific binding molecules
PT3247728T (pt) * 2015-01-20 2020-07-16 Igm Biosciences Inc Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas
KR102357312B1 (ko) * 2015-03-04 2022-02-03 아이쥐엠 바이오사이언스 인코포레이티드 Cd20 결합 분자 및 그의 용도
WO2016154593A1 (en) * 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
US20190330374A1 (en) * 2016-07-20 2019-10-31 Igm Biosciences, Inc. Multimeric ox40 binding molecules and uses thereof
CA3030659A1 (en) * 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric gitr binding molecules and uses thereof
CA3055790A1 (en) * 2017-04-07 2018-10-11 Igm Biosciences, Inc. Modified human igm constant regions for modulation of complement-dependent cytolysis effector function

Similar Documents

Publication Publication Date Title
KR20210083260A (ko) 다가 IgM- 및 IgA-Fc 기반 결합 분자
US11572388B2 (en) Chimeric polypeptides and uses thereof
CN107428830B (zh) 单体fc结构域
JP2022504822A5 (cg-RX-API-DMAC7.html)
WO2020142625A4 (en) Compositions for increasing half-life of a therapeutic agent in canines and methods of use
CN118852460A (zh) 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白;TRAAFFIAA)
JP2024504728A5 (cg-RX-API-DMAC7.html)
RU2020118832A (ru) Биспецифические слитые полипептиды и способы их применения
US20230045794A1 (en) Nk cell-directed chimeric proteins
US12448465B2 (en) Peptides
JP2022548112A5 (cg-RX-API-DMAC7.html)
KR20240024858A (ko) sPD-1과 IL-15를 갖는 이중특이적 Fc 융합 단백질
JP2023538902A (ja) 操作されたリガンドを使用する材料及び方法
CN115724984A (zh) 自身免疫b细胞消除剂分子及其用途
US20260049118A1 (en) Single-chain chimeric polypeptides and uses thereof
US20260132185A1 (en) Multi-chain chimeric polypeptides and uses thereof
WO2022262832A1 (zh) 双特异性融合蛋白
RU2021131461A (ru) Биспецифичный слитый белок и его применение
RU2023135094A (ru) ВАРИАНТ Fc С ПОВЫШЕННОЙ АФФИННОСТЬЮ К Fc-РЕЦЕПТОРАМ И УЛУЧШЕННОЙ ТЕРМИЧЕСКОЙ СТАБИЛЬНОСТЬЮ